Aftertreated Polymer (e.g., Grafting, Blocking, Etc.) Patents (Class 424/78.17)
  • Patent number: 10954266
    Abstract: The present invention relates to a method for the purification of peptides which are produced by solid phase peptide synthesis (SPPS) and corresponding linker molecules for use in said method.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 23, 2021
    Assignee: BELYNTIC GMBH
    Inventors: Robert Zitterbart, Oliver Seitz
  • Patent number: 10947317
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Donald A. Bergstrom, Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Laura L. Poling, Aleksandr V. Yurkovetskiy
  • Patent number: 10869863
    Abstract: Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 22, 2020
    Assignee: BrightGene Bio-Medical Technology Co., Ltd.
    Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
  • Patent number: 10831169
    Abstract: The present disclosure relates to a manufacturing system, method and control circuitry for quality assured manufacturing of at least two biopharmaceutical products. The manufacturing system comprises a warehouse facility, a hydration facility, and at least two biopharmaceutical manufacturing facilities, wherein the warehouse facility and hydration facility are comprised in the macro structure. Each biopharmaceutical manufacturing facility is comprised in a respective micro node, and a control facility in the macro structure is configured to control interoperability of the macro structure and the micro nodes by means of a network spine interconnecting the macro structure with each micro node.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 10, 2020
    Assignee: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
    Inventors: Steve Robert Gravallese, Jason Naylor, Edwin Brian Taylor, Sven Frie, Patrick McMahon
  • Patent number: 10800749
    Abstract: In alternative embodiments, the invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino-acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: October 13, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Palmer Taylor, Zoran Radic, K. Barry Sharpless, Valery Fokin, Rakesh Sit
  • Patent number: 10772844
    Abstract: A hybrid hydrogel including a hydrogel material and a plurality of first hybrid nanoparticles is provided. The plurality of first hybrid nanoparticles are conjugated to the hydrogel material, wherein each of the first hybrid nanoparticles includes a first positive-charged polysaccharide and a first negative-charged polysaccharide. The first positive-charged polysaccharide is located at an inner core of the first hybrid nanoparticles. The first negative-charged polysaccharide is located at an outer shell of the first hybrid nanoparticles and carries a plurality of first growth factors. The first negative-charged polysaccharide and the first positive-charged polysaccharide are electrostatically attracted to form the first hybrid nanoparticles. A method of fabricating the hybrid hydrogel is also provided.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: September 15, 2020
    Assignee: National Tsing Hua University
    Inventors: Tzu-Wei Wang, Wei-Hong Jian
  • Patent number: 10577406
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 3, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • Patent number: 10532125
    Abstract: The presently-disclosed subject matter includes a compound comprising a first monomer, which is allyl-functionalized and crosslinkable, and a second monomer, which is not crosslinkable. In some embodiments the compounds are photocrosslinkable, and in certain embodiments are photocrosslinkable by ultraviolet light. Also provided are shape memory vascular grafts comprised the of present compounds that can transition from a temporary shape to an original shape when heated above a melting temperature of the graft. Still further provided are methods for treating vascular conditions that utilize embodiments of the present grafts.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 14, 2020
    Assignee: Vanderbilt University
    Inventors: Hak-Joon Sung, Timothy C. Boire, Mukesh K. Gupta, Angela L. Zachman, Sue Hyun-Lee, Colleen M. Brophy
  • Patent number: 10501575
    Abstract: Disclosed are biomimetic imageable polymeric materials that include a polymer or copolymer and a covalently-linked contrasting agent where the disclosed films are both bioresorbable and visible by X-ray fluoroscopic imaging and/or magnetic resonance imaging. The invention also provides methods of preparing the polymeric materials and their use in and as implantable medical devices.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: December 10, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Tre Raymond Welch, Amy Claire Kauffman
  • Patent number: 10400064
    Abstract: The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 3, 2019
    Assignee: Trustees of Boston University
    Inventors: Mark W. Grinstaff, Heng Zhang, Iriny Ekladious, Marlena D. Konieczynska
  • Patent number: 10398724
    Abstract: The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, ancurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: September 3, 2019
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: George Bourne, Michael Madden, Arthur R. Madenjian, Doreen Rao, Marcia Buiser, Jianmin Li, Raymond Rackley, Barry N. Gellman
  • Patent number: 10363259
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: July 30, 2019
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Nageswara R. Palepu
  • Patent number: 10363538
    Abstract: A substrate for biochips, in which carboxyl groups are immobilized on a substrate whose surface at least is composed of carbon; and a method for producing the substrate are disclosed. The substrate for biochips comprises a substrate whose surface at least is composed of carbon; and an acrylic polymer having free carboxyl groups in the molecular structure thereof, which acrylic polymer is immobilized on the surface of the substrate. The method for producing the substrate comprises irradiating the substrate whose surface at least is composed of carbon with ultraviolet light during the acrylic polymer having free carboxyl groups in the molecular structure thereof contacts the substrate.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: July 30, 2019
    Assignee: NIPPON LIGHT METAL COMPANY, LTD.
    Inventors: Yasushi Takebayashi, Ryo Morishita, Kei Yamaguchi
  • Patent number: 10342797
    Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 9, 2019
    Assignee: LivePet, LLC
    Inventors: Ian Mitchell, Daniel David Bensimon, Ayyappan Subbiah, Rajashekharam Malyala
  • Patent number: 10336708
    Abstract: A novel imidazole compound that yields a surface treatment liquid that is very effective at suppressing migration and oxidation of a wiring surface; a metal surface treatment liquid that contains the imidazole compound; a metal surface treatment method that uses the metal surface treatment liquid; and a laminate production method that uses the surface treatment liquid. A metal is surface-treated using the surface treatment liquid which includes a saturated fatty acid or a saturated fatty acid ester of a specific structure, in which a prescribed position is substituted by an aromatic group of a prescribed structure and an imidazolyl group that may have a substituent group.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 2, 2019
    Assignee: TOKYO OHKA KOGYO CO., LTD.
    Inventors: Tatsuro Ishikawa, Kunihiro Noda, Yasuhide Ohuchi, Hiroki Chisaka, Dai Shiota, Yukitsugu Maeda, Takafumi Imoto, Kouhei Fujita, Yasuyuki Akai
  • Patent number: 10266809
    Abstract: A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 23, 2019
    Assignee: STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Alan Edward Rowan, Zaskia Hillet Eksteen Akeroyd, Christopher Wilson, Petrus Johannes Geutjes, Wouter F. J. Feitz, Egbert Oosterwijk
  • Patent number: 10195135
    Abstract: The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived copolymer segment containing a repeating unit derived from an unsaturated monomer containing a carboxylic acid or a carboxylic acid salt as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is 35 to 59% by mass, a content of the repeating unit derived from the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt in the organopolysiloxane graft polymer is 4 to 17% by mass, and a content of a repeating unit derived from an unsaturated monomer whose homopolymer has a glass transition point of not lower than 150° C.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: February 5, 2019
    Assignee: KAO CORPORATION
    Inventors: Satomi Nakazono, Ryosuke Fujii
  • Patent number: 10154956
    Abstract: Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 18, 2018
    Assignee: Carnegie Mellon University
    Inventor: Alex Evilevitch
  • Patent number: 10149885
    Abstract: A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: December 11, 2018
    Assignee: STARPHARMA PTY LIMITED
    Inventors: Jacinth Kincaid Fairley, Colin Paul Barrett, Jeremy Robert Arthur Paull
  • Patent number: 10022453
    Abstract: The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 17, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Sven Wittrock, Nils Griebenow, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Mario Lobell, Carsten Terjung, Simone Greven, Yolanda Cancho Grande
  • Patent number: 9999675
    Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 19, 2018
    Assignee: Surmodics, Inc.
    Inventors: Joseph Ventura, Shannon Wadman, Joram Slager, Joseph Schmidt McGonigle, Robert W. Hergenrother
  • Patent number: 9993500
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: June 12, 2018
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 9974188
    Abstract: A process for forming a graphene circuit pattern on an object is described. A graphene layer is grown on a metal foil. A bonding layer is formed on a protective film and a surface of the bonding layer is roughened. The graphene layer is transferred onto the roughened surface of the bonding layer. The protective film is removed and the bonding layer is laminated to a first core dielectric substrate. The metal foil is etched away. Thereafter the graphene layer is etched using oxygen plasma etching to form graphene circuits on the first core dielectric substrate. The first core dielectric substrate having graphene circuits thereon is bonded together with a second core dielectric substrate wherein the graphene circuits are on a side facing the second core dielectric substrate wherein an air gap is left therebetween.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Compass Technology Company Limited
    Inventors: Kelvin Po Leung Pun, Chee Wah Cheung
  • Patent number: 9962676
    Abstract: Disclosed herein is a method of: treating an organic polymer with an electron beam-generated plasma; exposing the treated polymer to air or an oxygen- and hydrogen-containing gas, generating hydroxyl groups on the surface of the polymer; reacting the surface with an organosilane compound having a chloro, fluoro, or alkoxy group and a functional or reactive group that is less reactive with the surface than the chloro, fluoro, or alkoxy group; and covalently immobilizing a biomolecule to the functional or reactive group or a reaction product thereof.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: May 8, 2018
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Stella H. North, Evgeniya H. Lock, Scott G. Walton, Chris Rowe Taitt
  • Patent number: 9938376
    Abstract: A furan-based polyamide is prepared by the following steps: (1) preparing a furan-based oligomer of formula (1) H2N—R—(NH—CO—F—CO—NH—R)n—NH2 (1) where R is a hydrocarbon moiety and F is a furan (cyclo-C4H2O) moiety and n represents the average degree of oligomerization, and where n is within the range of 1 to 10 by reacting 2,5-furandicarboxylic acid or its derivative with a diamine at a temperature of at most 100° C.; (2) contacting the oligomer of step (1) with a bifunctional linker selected from an acid or a derivative thereof where the acid is furandicarboxylic acid or a non-aromatic dicarboxylic acid; provided that if the hydrocarbon moiety R is aromatic, then the bifunctional linker is an aromatic dicarboxylic acid or a derivative thereof, at a mole ratio of the oligomer to the difunctional linker within the range of 0.8 to 1.5 at polycondensation conditions, and (3) isolating the resulting polyamide.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: April 10, 2018
    Assignee: Synvina C.V.
    Inventors: Ate Duursma, Rene Aberson, Dee Dee Smith, Joel Flores, Matheus Adrianus Dam, Gerardus Johannes Maria Gruter
  • Patent number: 9896412
    Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: February 20, 2018
    Assignee: POLYTHERICS LIMITED
    Inventor: Antony Godwin
  • Patent number: 9801892
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 31, 2017
    Assignee: HAZ TWO, LLC
    Inventor: Nageswara R. Palepu
  • Patent number: 9801978
    Abstract: Medical constructs with collagen fibers and gelatin and related collagen fibers. The collagen fibers can be derived from extruded soluble dermal collagen and can include a gelatin film attached to the at least one collagen fiber. The gelatin film can include one or more minerals and has a gelatin concentration of between about 0.1% to about 40% weight per volume.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: October 31, 2017
    Assignee: MiMedx Group, Inc.
    Inventors: Leon Paulos, Mengyan Li, Daniel Hernandez, Thomas Koob
  • Patent number: 9790286
    Abstract: This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, antagonize or disrupt, simultaneously and independently, the functional domain of different disease causing proteins.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 17, 2017
    Inventor: Lucia Irene Gonzalez
  • Patent number: 9744246
    Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: August 29, 2017
    Assignee: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Patent number: 9731288
    Abstract: The present invention provides novel and improved stimulus responsive polymers and methods of using the same for the purification of biomolecules.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 15, 2017
    Assignee: EMD Millipore Corporation
    Inventors: Jad Jaber, Wilson Moya, James Hamzik, Arezki Boudif, Yu Zhang, Neil Soice, John Charkoudian, Nripen Singh
  • Patent number: 9625467
    Abstract: A method and related agent for detecting novel post-translational modification. This novel post-translational modification is in the form of crotonylation of lysine residues in proteins. The method includes the steps of (a) preparing a mixture of polypeptides from a protein sample; (b) separating the polypeptides by molecular weight; (c) contacting the separated polypeptides with a binding affinity reagent which binds specifically to a polypeptide containing a crotonyllysine residue; and (d) detecting presence of a binding complex between the affinity reagent and one or more of the polypeptides. An example of the binding agent is an antibody, which may be prepared from animal serums, or is a monoclonal antibody or single-chain variable fragment.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: April 18, 2017
    Assignee: PTM BIO LLC
    Inventor: Yingming Zhao
  • Patent number: 9555119
    Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 31, 2017
    Assignee: Surmodics, Inc.
    Inventors: Joseph Ventura, Shannon Wadman, Joram Slager, Joseph Schmidt McGonigle, Robert W. Hergenrother
  • Patent number: 9549901
    Abstract: A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 24, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Jinjun Shi, Zeyu Xiao, Cristian Vilos, Alexander Votruba, Robert S. Langer, Omid C. Farokhzad
  • Patent number: 9474804
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Patent number: 9468681
    Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 18, 2016
    Assignee: California Institute of Technology
    Inventors: Mark E. Davis, Han Han
  • Patent number: 9415076
    Abstract: The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: August 16, 2016
    Assignee: Wake Forest University Health Sciences
    Inventors: Anthony Atala, James Yoo, In Kap Ko
  • Patent number: 9308180
    Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 12, 2016
    Assignee: Abraxis BioScience, LLC
    Inventors: Tapas De, Neil P Desai, Andrew Yang, Zachary Yim, Patrick Soon-Shiong
  • Patent number: 9301972
    Abstract: The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 5, 2016
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Kenji Miyamoto
  • Patent number: 9295693
    Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: March 29, 2016
    Assignee: Eyeon Particle Sciences LLC
    Inventors: Eugene Rex Cooper, David Maxwell Kleinman, Andrew Loxley, Mark Mitchnick
  • Patent number: 9283169
    Abstract: The present invention relates to a water-in-oil emulsified skin cosmetic comprising the following ingredients (a) through (e): (a) Water: 5-50 wt % (b) Ethanol: 1-20 wt % (c) Volatile oil component: 2-50 wt % (d) Carboxy decyl trisiloxane represented by the following formula (1): 0.1-5 wt % (e) One, two or more selected from a group consisting of hydrophobized titanium dioxide, hydrophobized zinc oxide, and hydrophobized iron oxide: 2-50 wt %; wherein the object of the present invention is to provide a water-in-oil emulsified skin cosmetic containing the aforementioned powder (e) wherein powdery squeakiness over time after application on the skin is suppressed and at the same time absorption into the skin at the time of application and the absence of stickiness after application on the skin are improved.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 15, 2016
    Assignee: SHISEIDO COMPANY, LTD.
    Inventor: Kazutaka Sasaki
  • Patent number: 9205107
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: December 8, 2015
    Assignee: Tricida, Inc.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 9205103
    Abstract: A hydrogel formulation of oxidized dextrin is reticulated with adipic acid dihydrazide, which may embody polysaccharides, proteins, nanogels, granular materials, bioactive molecules and cells for tissue regeneration and controlled drug delivery. A hydrogel can be injectable, highly biocompatible and biodegradable, for tissue regenerative applications, performing simultaneously as a vehicle e.g. for nanogels, granular materials and cells, and as controlled drug delivery systems, e.g. of hydrophobic molecules and therapeutic proteins.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: December 8, 2015
    Assignee: UNIVERSIDADE DO MINHO
    Inventors: Francisco Miguel Portela Da Gama, Maria Cabral Maio Molinos
  • Patent number: 9180088
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: November 10, 2015
    Assignee: SCIDOSE, LLC
    Inventor: Nageswara R. Palepu
  • Patent number: 9161993
    Abstract: The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least ?2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least ?1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 20, 2015
    Assignee: Danmarks Tekniske Universitet
    Inventors: Rasmus Irming Jølck, Jonas Rosager Henriksen, Torben Gjetting, Thomas Lars Andresen
  • Patent number: 9125973
    Abstract: A method for immobilizing dyes and antimicrobial agents on a polymeric cover or housing for a medical device is disclosed and described. The surface may be that of a catheter, a connector, a drug vial spike, a bag spike, a prosthetic device, an endoscope, a surface of an infusion pump, a key pad, a touch screen or a handle. The surfaces may also be one or more of those associated with a infusion of a medicament or dialysis treatment, such as peritoneal dialysis or hemodialysis, where it is important that the working surface for the dialysis fluid be sterile. These surfaces include connectors for peritoneal dialysis sets or for hemodialysis sets, bag spikes, dialysis catheters, and so forth. A method for determining whether a surface has been sterilized, and a dye useful in so indicating, is also disclosed.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: September 8, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Tuan Bui, Ton That Hai, Mark Nordhaus, Paul Sanders, Cong Jiang, David Lamb, Ozlem Yardimci
  • Patent number: 9089611
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 28, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Patent number: 9073011
    Abstract: A diesel oxidation catalyst (DOC) catalytic converter for at least the conversion of carbon monoxide and hydrocarbons, removal of a fraction of particulate matter, and decrease of sulfur trioxide emissions within exhaust gases from an engine and consequently of sulfuric acid, is disclosed. The DOC may include any suitable configuration including at least a substrate and a washcoat, where the substrate has a plurality of channels, suitable porosity, offers a three-dimensional support for the washcoat, and is made of any suitable material. The washcoat may be deposited on the substrate by any suitable method, and may include a mixture of at least one or more carrier material oxides and one or more catalysts. Suitable materials for the carrier material oxides may include titanium dioxide, tin dioxide, and zirconium dioxide, among others, excluding aluminum oxide (Al2O3), which may serve for a decrease of sulfur trioxide emissions and consequently of sulfuric acid mist.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: July 7, 2015
    Inventor: Randal Hatfield
  • Patent number: 9045494
    Abstract: A compound is provided that is useful for, among other things, preparing water-soluble polymer derivatives bearing a terminal N-succinimidyl ester.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: June 2, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventor: Antoni Kozlowski
  • Patent number: 9040032
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: May 26, 2015
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray